Wilkins v. Austin III

CourtDistrict Court, E.D. Virginia
DecidedAugust 20, 2024
Docket1:22-cv-01272
StatusUnknown

This text of Wilkins v. Austin III (Wilkins v. Austin III) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wilkins v. Austin III, (E.D. Va. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Alexandria Division ISAIAH WILKINS, et al., ) Plaintiffs, v. 1:22-cv-1272 (LMB/IDD) LLOYD AUSTIN, II, et al., Defendants. MEMORANDUM OPINION In Harrison v. Austin and Roe v. Austin,' the Court held that the United States military’s policies prohibiting the commissioning and retention of asymptomatic HIV-positive service members with undetectable viral loads were irrational, arbitrary, and capricious, in violation of the equal protection component of the Fifth Amendment’s Due Process Clause and the Administrative Procedure Act. See 597 F. Supp. 3d 884 (E.D. Va. 2022), appeal dismissed sub. nom., Roe v. U.S. Dep’t of Def., 2022 WL 17423458 (4th Cir. July 11, 2022). The decisions in Harrison and Roe did not address whether the policies barring asymptomatic HIV-positive individuals with undetectable viral loads from joining the military also violate the Constitution and the APA. That question is now ripe for consideration. Plaintiffs Isaiah Wilkins, Carol Coe, Natalie Noe, and the Minority Veterans of America (collectively, “plaintiffs”) seek to eliminate this last major barrier to the full military service of asymptomatic HIV-positive individuals with undetectable viral loads by challenging the military’s categorical accessions bar.”

' Case Nos. 1:18-cv-641 and 1:18-cv-1565, respectively. “Accession” refers to appointment, enlistment, or induction into a military service. Appointment includes commissioning as an officer. See [Dkt. No. 58-3] DoDI 6130.03 at 56.

Before the Court are the parties’ cross-motions for summary judgment. Oral argument has been held, and for the reasons that follow, plaintiffs’ Motion for Summary Judgment, [Dkt. No. 57], will be granted and defendants’ Cross-Motion for Summary Judgment, [Dkt. No. 66], will be denied. I, A. Factual Background 1. HIV Treatment and Transmission The following factual background describing the current methods for treating HIV and the risk of transmitting the infection is taken from the United States Court of Appeals for the Fourth Circuit’s opinion in Roe, which, together with the full record in Harrison, has been incorporated into the record in this civil action. In the early 1980s, many young and otherwise healthy people became ill with “a wide array of rare and often deadly infections.” In the United States alone, thousands died. Researchers identified acquired immunodeficiency syndrome (AIDS) as the reason so many otherwise healthy people died from these infections, but they did not understand the cause of AIDS. The people most frequently diagnosed with AIDS belonged to marginalized and stigmatized groups—gay men, intravenous drug users, Haitians, and hemophiliacs—and the disease acquired the colloquial moniker “gay cancer.” In 1984, researchers discovered that AIDS was caused by the human immunodeficiency virus (HIV), which could infect any person sufficiently exposed. However, “by that time, many Americans already believed the cause of the disease to be a deviant lifestyle, a stigmatizing belief that ... AIDS was a punishment from God.” Stigma, fear, and misinformation about HIV persist today. Unlike some viruses, HIV is not easily transmitted. It cannot be spread by saliva, tears, or sweat, and it is not transmitted through hugging, handshaking, sharing toilets, exercising together, or closed-mouth kissing. HIV may be transmitted when certain

3 The Court and plaintiffs have repeatedly emphasized that the records from both Harrison and Roe are “to some degree, the law of the case.” See [Dkt. No. 56] at 11; [Dkt. No. 64]; [Dkt. No. 125] at 10-11.

infected body fluids—blood, semen, pre-seminal fluid, rectal and vaginal fluids, and breastmilk—encounter damaged tissue, a mucous membrane, or the bloodstream. However, even then, transmission is unlikely. The Centers for Disease Control and Prevention estimate the per-exposure risk of transmitting untreated HIV during the riskiest sexual activity—receptive anal intercourse—to be 1.38%. For other sexual activities, the per- exposure risk of transmitting untreated HIV drops to between 0% and 0.11%. And although the risk of transmitting untreated HIV through blood transfusion is high, people who have been diagnosed with HIV are not permitted to donate blood. Untreated HIV can also be transmitted through other types of exposure, but the risk is low. For needle sharing, the per-exposure risk is 0.63%, and for percutaneous needlestick injuries, the per-exposure risk is 0.23%. For other exposures to untreated HIV—like biting, spitting, and throwing bodily fluids—the CDC found the risk to be “negligible,” meaning transmission of untreated HIV is “technically possible but unlikely and not well documented.” In 1996, antiretroviral therapy for HIV became widely available. Today, there is “an effective treatment regimen for virtually every person living with HIV,” and 75% to 80% of people living with HIV are on a one-tablet antiretroviral regimen, which combines the required medications into a single pill taken daily. The pills have no special handling or storage requirements and tolerate extreme temperatures well. They have minimal side effects and impose no dietary restrictions. And with adherence to treatment, an HIV- positive person’s viral load becomes “suppressed” within several months and the virus reaches “undetectable” levels shortly thereafter, meaning there are less than 50 virus copies per milliliter of blood. In addition to medication, individuals with HIV receive viral load testing, which is usually conducted quarterly until the patient reaches an undetectable viral load. Then, testing is reduced to three times a year, and finally, once the viral load is undetectable for two years, testing is reduced to a semiannual basis. Testing is routine and can be performed by a general practitioner. Where on- site testing is unavailable, a blood sample can be shipped to a lab. Antiretroviral therapy is effective for virtually every person living with HIV. Usually, the virus develops resistance to antiretroviral therapy only when individuals fail to adhere to their treatment regimens. But even then, switching to a different regimen returns the individual to viral suppression. And failing to adhere to treatment does not result in immediate adverse health consequences. It “often takes weeks for an individual’s viral load to reach a level that would not be considered ‘suppressed.’” If nonadherence

continues, the person enters a clinical latency period during which the person may not have any symptoms or negative health outcomes. This clinical latency period “can last for years,” and “can be reversed by restarting treatment.” Antiretroviral therapy has both increased the quality of life of individuals with HIV and decreased the chance of transmission. In contrast to the fraction-of-a-percent exposure risks for untreated HIV addressed above, according to the CDC, “people who take antiretroviral medication daily as prescribed and achieve and maintain an undetectable viral load have effectively no risk of sexually transmitting the virus to an HIV negative partner.” And other than through blood transfusions—again, “HIV infection is among a number of medical conditions that preclude blood donation”—risk of transmission from a person with an undetectable viral load through non-sexual means such as _ percutaneous needlestick injuries is very low, if such a risk exists at all. An HIV diagnosis was “once considered invariably fatal within approximately eight to ten years,” but now, HIV is a “chronic, treatable condition.” Those who are timely diagnosed and treated “experience few, if any, noticeable effects on their physical health and enjoy a life expectancy approaching that of those who do not have HIV.” Roe v. Dept’ of Def., 947 F.3d 207, 212-14 (4th Cir. 2020) (record citations omitted).* 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Reaves v. Ainsworth
219 U.S. 296 (Supreme Court, 1911)
Orloff v. Willoughby
345 U.S. 83 (Supreme Court, 1953)
Shuttlesworth v. City of Birmingham
394 U.S. 147 (Supreme Court, 1969)
Plyler v. Doe
457 U.S. 202 (Supreme Court, 1982)
City of Cleburne v. Cleburne Living Center, Inc.
473 U.S. 432 (Supreme Court, 1985)
Heller v. Doe Ex Rel. Doe
509 U.S. 312 (Supreme Court, 1993)
Madsen v. Women's Health Center, Inc.
512 U.S. 753 (Supreme Court, 1994)
United States v. Virginia
518 U.S. 515 (Supreme Court, 1996)
Norfolk Southern Railway Co. v. City of Alexandria
608 F.3d 150 (Fourth Circuit, 2010)
Ostergren v. Cuccinelli
615 F.3d 263 (Fourth Circuit, 2010)
Ursack, Inc. v. Sierra Interagency Black Bear Group
639 F.3d 949 (Ninth Circuit, 2011)
Emerson Emory v. Secretary of the Navy
819 F.2d 291 (D.C. Circuit, 1987)
Diaz v. Brewer
656 F.3d 1008 (Ninth Circuit, 2011)
Craigmiles v. Giles
312 F.3d 220 (Sixth Circuit, 2002)
Armour v. City of Indianapolis
132 S. Ct. 2073 (Supreme Court, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Wilkins v. Austin III, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wilkins-v-austin-iii-vaed-2024.